期刊文献+

氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者疗效研究 被引量:6

Observation on the Clinical Efficacy of Losartan Potassium and Hydrochlorothiazide in Treating Hypertensive Patients Ineffective Controlled by Angiotensin Receptor Blockers
下载PDF
导出
摘要 目的:研究应用氯沙坦氢氯噻嗪合剂治疗血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者的治疗效果及安全性。方法:选取2010年1月至2012年12月间在我院治疗的80例服用血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者作为研究对象,采用氯沙坦钾氢氯噻嗪片对患者进行治疗,每日1片(含氯沙坦钾50mg,氢氯噻嗪12.5mg),晨起顿服。疗程共8周,治疗过程中监测患者血压、心率、血糖、血脂、电解质、血尿酸、肝肾功能等指标,以评价药物的治疗效果及安全性。结果:80例患者中,共75例完成治疗,治疗后患者平均血压由163.4±9.8/107.5±8.7(收缩压/舒张压)下降到137.4±8.3/88.7±7.8,血压控制率达77.3%;实验中患者未出现低钾血症等严重不良反应,仅1例患者因头晕退出治疗,不良反应发生率为1.3%。结论:氯沙坦氢氯噻嗪合剂对血管紧张素Ⅱ受体拮抗剂控制无效的高血压患者具有显著疗效,且安全可靠。 Objective: To observe the clinical efficacy of losartan hydrochlorothiazide mixture in treating hypertensive patients ineffective controlled by angiotensin receptor blockers. Method: Selected 80 patients ineffective controlled by angiotensin receptor blockers who received treatment in our hospital from Jan. 2010to Dec. 2012 for experiment objects. Losartan potassium and hydrochlorothiazide tablets was received 1 tablet per day to control their blood pressure. The treatment lasted 8 weeks,and the blood pressure,heart rate,blood glucose,blood lipids,electrolytes,uric acid,liver and renal function were monitored to evaluate the clinical efficacy and safety. Result: Of all the patients,75 cases finished the treatment,the blood pressure decreased from 163.4±9.8 /107.5±8.7 mmHg( SBP / DBP) to 137.4±8.3 /88.7±7.8 mmHg,blood pressure control rates was 77.3%,no adverse reaction was observed,and only 1 patient( 1.3%) quitted for headache.Conclusion: Losartan potassium and hydrochlorothiazide tablets is very effective and safe in treating hypertensive patients ineffective controlled by angiotensin receptor blockers.
作者 袁锋 管春静
出处 《河北医学》 CAS 2014年第2期210-213,共4页 Hebei Medicine
关键词 氯沙坦钾氢氯噻嗪片 高血压 血管紧张素Ⅱ受体拮抗剂 Losartan potassium and hydrochlorothiazide tablets Hypertension AngiotensinⅡ receptor blockers
  • 相关文献

参考文献6

  • 1刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-708. 被引量:6940
  • 2Zhang Y, Zhang X, Lin L, et al. Is a systolic blood pressure target< 140 mmHg indicated in all hypertensive subgroup an- alyses of findings from the randomized fever trial [ J ]. Eur Heart, 2011, 32(12) :1500-1508.
  • 3Gong I_S, Zhang WH, Zhu Y J, et al. Shanghai trial of nife- dipine in the elderly (STONE) [ J]. Hypertens, 2008, 14 (6) :1237-1245.
  • 4Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pres- sure lowering and metabolic effects of thiazide and thia-- ideOlike diuretics [ J]. Expert Rev Cardiovasc Ther, 2010, 8 (6) :793-802.
  • 5Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy [J].Am J Hypertens, 2000,13(4 PT 1) :418-426.
  • 6ux RB, Kjeldsen SE, et al. Cardiovascular morbidity andmortality in the losartan intervention for endpoint reduction in hypertensive study (LIFE) : a randomized trial against atenolo[ J] .Lancet, 2002, 259( 9311 ) :995-1003.

二级参考文献29

共引文献6939

同被引文献58

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部